報價延遲最少15分鐘:2024/12/23 22:27 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.76 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.64/-4.95
|
|
企業價值
30.24M
|
| 資產負債 |
|
每股賬面淨值
2.99
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
7.30M
|
|
每股收益
1.90
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:27 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmetmedical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. |